Assets
Target
Indication
Regulatory Authority
Stage
Pre-clinical
Phase 1
Phase 2
Phase 3
NDA
Commercial Rights
Small Molecule
  • IPG11406
    EBI2
    (GPR183)
    SLE/LN
    IBD/UC
    China NMPA
    U.S. FDA
    China NMPA
    U.S. FDA
    Phase 1b/2a Ongoing
    IND Approval
    Phase 1 Completed
    IND Approval
    Global
  • IPG1094
    MIF
    Brain Metastatic NSCLC (BM)
    Ischaemic Stroke (IS)
    China NMPA
    U.S. FDA
    China NMPA
    U.S. FDA
    Phase 1/2a Ongoing
    Phase 1 Completed (Australia)
    IND Approval
    IND Approval
    Global
  • IPG7236
    CCR8
    IgG4-Related Diseases
    Solid Tumor
    China NMPA
    U.S. FDA
    China NMPA
    U.S. FDA
    IND Approval
    Phase 1 Ongoing (Australia)
    Phase 1/2a MRCT Ongoing
    Phase 1/2a MRCT Ongoing
    Global
  • IPG6620
    LPAR5(GPR92)
    Chemotherapy Induced Peripheral Neuropathy (CIPN)
    China NMPA
    U.S. FDA
    Pre-clinical
    Pre-clinical
    Global
  • IPG8294
    CD38 NADase
    Neurological Diseases
    China NMPA
    U.S. FDA
    Phase 1 Ongoing
    IND Approval Obtained
    Licensed-out
Monoclonal Antibody
  • IPG0521
    CCR8
    Solid Tumor
    China NMPA
    U.S. FDA
    IND Approval Obtained
    IND Approval Obtained
    Global
  • IPG0916
    CCR6
    Autoimmune Diseases
    China NMPA
    Pre-clinical
    Global
Assets
Target
Indication
Regulatory Authority
Stage
Pre-clinical
Phase 1
Phase 2
Phase 3
NDA
Commercial Rights
Small Molecule
  • IPG11406
    EBI2
    (GPR183)
    SLE/LN
    IBD/UC
    China NMPA
    U.S. FDA
    China NMPA
    U.S. FDA
    Phase 1b/2a Ongoing
    IND Approval
    Phase 1 Completed
    IND Approval
    Global
  • IPG1094
    MIF
    Brain Metastatic NSCLC (BM)
    Ischaemic Stroke (IS)
    China NMPA
    U.S. FDA
    China NMPA
    U.S. FDA
    Phase 1/2a Ongoing
    Phase 1 Completed (Australia)
    IND Approval
    IND Approval
    Global
  • IPG7236
    CCR8
    IgG4-Related Diseases
    Solid Tumor
    China NMPA
    U.S. FDA
    China NMPA
    U.S. FDA
    IND Approval
    Phase 1 Ongoing (Australia)
    Phase 1/2a MRCT Ongoing
    Phase 1/2a MRCT Ongoing
    Global
  • IPG6620
    LPAR5(GPR92)
    Chemotherapy Induced Peripheral Neuropathy (CIPN)
    China NMPA
    U.S. FDA
    Pre-clinical
    Pre-clinical
    Global
  • IPG8294
    CD38 NADase
    Neurological Diseases
    China NMPA
    U.S. FDA
    Phase 1 Ongoing
    IND Approval Obtained
    Licensed-out
Monoclonal Antibody
  • IPG0521
    CCR8
    Solid Tumor
    China NMPA
    U.S. FDA
    IND Approval Obtained
    IND Approval Obtained
    Global
  • IPG0916
    CCR6
    Autoimmune Diseases
    China NMPA
    Pre-clinical
    Global

Cpyright © 2025 Nanjing Immunophage Biomedical Co.,Ltd

All Rights Reserved.  苏ICP备2022026466号-1  备案.png苏公网安备 32011202000830号